Feasibility of triweekly docetaxel-based chemotherapy for elderly patients (age 75 and older) with castration-resistant prostate cancer.
Feasibility of triweekly docetaxel-based chemotherapy for elderly patients (age 75 and older) with castration-resistant prostate cancer.
复制标题
对于患有去势抵抗性前列腺癌的老年患者（75 岁及以上），每三周进行一次基于多西紫杉醇的化疗的可行性。
DOI：
10.1200/jco.2011.29.15_suppl.e15092
复制
发表时间：
2011
影响因子：
45.3
通讯作者：
T. Miki
中科院分区：
文献类型：
--
作者：
N. Takaha;T. Iwata;T. Nakamura;F. Hongo;K. Kamoi;K. Okihara;A. Kawauchi;T. Miki
背景：两项试验（TAX327和SWOG 99-16）证明了每三周以多西他赛为基础的化疗治疗去势抵抗性前列腺癌（CRPC）患者的生存获益。尽管老年前列腺癌（PCa）患者的管理正在成为许多国家主要的公共卫生问题，但关于75岁或以上的老年CRPC患者的多西他赛最佳方案的报道很少。本研究的目的是评估以多西他赛为基础的化疗对75岁及以上高龄转移性CRPC患者的疗效和安全性。
e15092 Background:A survival benefit of tri-weekly docetaxel-based chemotherapy for castration-resistant prostate cancer (CRPC) patients was demonstrated by two trials, TAX327 and SWOG 99-16. Even though the management of elderly prostate cancer (PCa) patients is becoming a major public health concern in many countries, there are few reports regarding the optimal protocol of docetaxel for elderly CRPC patients, who are 75 years or older. The aim of this study is to evaluate the efficacy and safety of docetaxel-based chemotherapy for elderly metastatic CRPC patients at the age of 75 or higher.
METHODS
A total of 51 CRPC patients were treated by a regimen of docetaxel (70mg/m2) once every 3 weeks (3qw) in combination with oral dexamethasone or estramustine. Adjustment for docetaxel dosage and period per cycle was subject to investigator's judgment. The efficacy and safety of 20 patients at the age of 75 or higher (older group) were compared to those of 31 patients younger than 75 years (younger group).
RESULTS
Median age was 72 years (55-88). The median relative dose intensity of both groups was 0.84 without any significant difference, while the median dose intensity and the number of treatment cycles of younger group and older group were, 14.6 vs 12.3 mg/m2/week (P=0.021), and 9 vs 8 cycles (P=0.15), respectively. In the older group of patients, PSA response rate was 50%, median time to biochemical progression was 7.5 months, and median survival time was 15.5 months, without any significant difference compared to those of younger group. No significant difference was demonstrated in the incidence of grade 3-4 adverse events observed in both groups. All these parameters for efficacy as well as discontinuation rate because of adverse events in this study are comparable to those reported previously for CRPC patients treated by a regimen of docetaxel 3qw.
CONCLUSIONS
Treatment by docetaxel (70 mg/m2) 3qw with proper adjustment might contribute to maintaining the efficacy and safety of the treatment for elderly CRPC patients.